{"id":"NCT01900444","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of a Booster Dose of IMOJEV速 One Year After Primary Immunization in Healthy Children in South Korea","officialTitle":"Immunogenicity and Safety Exploration of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV速) Given One Year After Primary Immunization in Healthy Children in South Korea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07-11","primaryCompletion":"2014-03-11","completion":"2014-03-11","firstPosted":"2013-07-16","resultsPosted":"2017-12-13","lastUpdate":"2022-03-28"},"enrollment":119,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"IMOJEV","otherNames":["Japanese Encephalitis Chimeric Virus Vaccine"]}],"arms":[{"label":"IMOJEV Group","type":"EXPERIMENTAL"}],"summary":"The aim of this study was to document the immunogenicity and safety of a booster dose of IMOJEV administered at least 12 months after the primary dose.\n\nPrimary objective:\n\n* To describe the immune response to Japanese Encephalitis (JE) before and 28 days after a booster dose of IMOJEV administered at least 12 months after primary vaccination with IMOJEV.\n\nExploratory objectives:\n\n* To describe the safety profile of a booster dose of IMOJEV速 .","primaryOutcome":{"measure":"Percentage of Participants With JE Seroprotection Before and Following a Booster Dose of IMOJEV Given One Year After Primary Immunization","timeFrame":"Day 0 (pre-booster) and Day 28 post-booster injection","effectByArm":[{"arm":"Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV速)","deltaMin":93.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":8,"countries":["South Korea"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":119},"commonTop":["Malaise","Injection site Pain","Nasopharyngitis","Myalgia","Headache"]}}